Andrew Lightfoot PhD
Head of Medicinal Chemistry and Discovery Funding
Head of Medicinal Chemistry and Discovery Funding
Dr Andrew Lightfoot has an extensive career (23 years’) of leading successful R&D projects and joined Metrion in 2017 as Head of Medicinal Chemistry and Early Stage Funding.
Through Oaktree Bioscience Ltd, he also provides biotech CEO/drug discovery consultancy services to the VC community.
He was CEO of Procarta Biosystems (2017-20), an antibiotics company, raising over £10m in grants and equity. He was Founder, CEO/Director of Peptinnovate Ltd (now Revolo Biotherapeutics Ltd) from 2011-17, a clinical stage immunoinflammation biotech, which he successfully transitioned from early discovery to Phase 1, raising £7m in equity and grants funding.
In GlaxoSmithKline drug discovery (1998-2010), he discovered a number of molecules progressing to clinical trials and is inventor on >20 patents.
Let’s work together
What are your specific ion channel and assay needs?
If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.